SCHEMBL6715003

SCHEMBL6715003

O=S(=O)(Nc1ccc(C2=NCCc3ccc(Cl)cc32)cc1O)c1ccc2ccccc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 0.46
HSP90AB1 P08238 2/20 0.46
ERBB2 P04626 1/20 0.46
MAPK10 P53779 1/20 0.43
FBP1 P09467 2/20 0.41
HTR6 P50406 2/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
PGAM1 P18669 1/20 0.40
HKDC1 Q2TB90 1/20 0.40
RAD52 P43351 1/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CCR9 P51686 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6714720 0.87 MAPK10 (0.54) MAPK10HTR6CA1CA2CA7
SCHEMBL6723046 0.87 ATM (0.48) MAPK10FBP1HTR6MEN1KMT2A
SCHEMBL6720449 0.84 PFKFB3 (0.48) MAPK10FBP1HTR6MEN1KMT2A
SCHEMBL6718234 0.83 CCR9 (0.51) HSP90AA1HSP90AB1ERBB2FBP1CA1
SCHEMBL6718056 0.80 ATM (0.47) MAPK10FBP1CA1CA2CA7
SCHEMBL6724614 0.76 ATM (0.52) HTR6CA1CA2CA7CA9
SCHEMBL6718824 0.76 ATM (0.47) HTR6MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL6716880 0.76 MEN1 (0.55) MAPK10CA1CA2CA7CA9
SCHEMBL6724676 0.74 PGR (0.62) HTR6
SCHEMBL6718746 0.73 DRD2 (0.48) MAPK10HTR6CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818651-B2 ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE ALTANA PHARMA AG (DE) 2004-11-16 US disclosed
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors ALTANA PHARMA AG (DE) 2004-03-04 US disclosed
EP-1337515-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2003-08-27 EP disclosed
WO-2002040450-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS ALTANA PHARMA AG (DE) 2002-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors PDE7B, PDE3B, PDE3A HSP90AA1 2991/4885HSP90AB1 3000/4885ERBB2 4781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.